INT139862

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 9
Disease Relevance 10.15
Pain Relevance 0.60

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
eye 1
superior 1
amd (Mus musculus)
Pain Link Frequency Relevance Heat
palliative 5 99.84 Very High Very High Very High
cva 39 96.72 Very High Very High Very High
cINOD 4 93.46 High High
Inflammation 100 84.44 Quite High
Pain 4 83.76 Quite High
alcohol 3 78.72 Quite High
Nicotine 3 76.16 Quite High
beta blocker 1 54.56 Quite High
agonist 19 50.00 Quite Low
corticosteroid 3 8.80 Low Low
Disease Link Frequency Relevance Heat
Age-related Macular Degeneration 802 100.00 Very High Very High Very High
Blindness 18 100.00 Very High Very High Very High
Diabetic Retinopathy 48 99.20 Very High Very High Very High
Retina Disease 8 97.52 Very High Very High Very High
Geographic Atrophy 19 97.00 Very High Very High Very High
Ocular Injury 29 96.72 Very High Very High Very High
Frailty 5 94.88 High High
Disease 49 94.24 High High
Mental Disorders 1 94.24 High High
Nicotine Addiction 42 88.48 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Patients with advanced AMD or vision loss due to advanced dry AMD in one eye have a 43% chance of developing CNV or geographic atrophy in the fellow eye within 5 years (AREDS 2001).
Negative_regulation (loss) of AMD in eye associated with age-related macular degeneration and geographic atrophy
1) Confidence 0.35 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012443 Disease Relevance 2.15 Pain Relevance 0
The overall prevalence of neovascular AMD in the US population 40 years and older is estimated to be 1.47%, with 1.75 million citizens having AMD (Friedman et al. 2004; AAO 2006).
Negative_regulation (prevalence) of AMD associated with age-related macular degeneration
2) Confidence 0.34 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012443 Disease Relevance 0.92 Pain Relevance 0
Currently, there is neither a cure nor a means to prevent AMD.
Negative_regulation (prevent) of AMD associated with age-related macular degeneration
3) Confidence 0.33 Published 2006 Journal Ann. Med. Section Abstract Doc Link 17101537 Disease Relevance 1.14 Pain Relevance 0.10
The AREDS formula does not address the vast majority of patients who want to improve visual function while preventing advanced AMD.
Negative_regulation (preventing) of AMD associated with age-related macular degeneration
4) Confidence 0.21 Published 2007 Journal BMC Ophthalmol Section Body Doc Link PMC1831760 Disease Relevance 0.36 Pain Relevance 0
The observed odds ratios were generally small, and there are limited interventions to prevent AMD.


Negative_regulation (prevent) of AMD associated with age-related macular degeneration
5) Confidence 0.20 Published 2010 Journal BMC Ophthalmol Section Body Doc Link PMC3009619 Disease Relevance 0.91 Pain Relevance 0
More recently, investigators compared 847 patients with AMD with 701 unaffected people and observed that a variant in the complement C3 gene affected the risk of developing AMD [86].
Negative_regulation (developing) of AMD associated with age-related macular degeneration
6) Confidence 0.06 Published 2008 Journal Semin Immunopathol Section Body Doc Link PMC2315691 Disease Relevance 1.09 Pain Relevance 0.13
It has superior corneal penetration compared to other NSAIDs and is bioactivated by ocular tissues to amfenac.8,15 Studies in rat models have indicated that it may play a role in inhibiting ocular neovascularization by inhibiting VEGF and retinal angiogenesis,16,17 and a recent case report showed topical nepafenac produced regression of intraretinal and subretinal macular edema and a reduction of fluorescein leakage in exudative AMD.18
Negative_regulation (reduction) of AMD in superior associated with cinod and age-related macular degeneration
7) Confidence 0.05 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2993124 Disease Relevance 0.56 Pain Relevance 0.29
common preventable cause of blindness in adults <50 years [4], whereas CNV/AMD
Negative_regulation (preventable) of AMD associated with blindness and age-related macular degeneration
8) Confidence 0.04 Published 2008 Journal PPAR Research Section Body Doc Link PMC2396446 Disease Relevance 2.24 Pain Relevance 0.05
Although exudative AMD is the leading cause of visual loss in patients above 60 years in western countries, conventional PDT with verteporfin can be given as a treatment in a minority of those with the disease [1].
Negative_regulation (loss) of AMD associated with disease and age-related macular degeneration
9) Confidence 0.02 Published 2005 Journal BMC Ophthalmol Section Body Doc Link PMC1314893 Disease Relevance 0.77 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox